AC
PFE icon

Ascend Capital’s Pfizer PFE Stock Holding History

Ascend Capital’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-527,000
Closed -$14.8M – 206
2014
Q2 		$14.8M Buy
+527,000
New +$15M 0.49% 68

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ascend Capital's PFE Position: Q3 2018 in Review

Ascend Capital opened a new position in Pfizer (PFE) in Q3 2018: 27,174 shares worth $1.14M. The stake represents 0.06% of the portfolio and ranks #142 among its holdings. This is a return to the name: Ascend Capital previously reported a position in PFE as recently as Q3 2017.

Ascend Capital first reported a position in PFE in Q2 2013 and has held it in 15 quarters since. The position peaked at $70.9M in Q3 2014. 2,256 funds tracked by Wall St. Rank hold PFE as of Q3 2018.

  • Ascend Capital held 27,174 shares of Pfizer worth $1.14M as of Q3 2018.
  • Pfizer was a new Ascend Capital position in Q3 2018.
  • Pfizer made up 0.06% of Ascend Capital's portfolio in Q3 2018, its #142 holding.
  • Ascend Capital first reported a position in Pfizer in Q2 2013 and has held it in 15 quarters since.
  • Ascend Capital's Pfizer position peaked at $70.9M in Q3 2014.
  • 2,256 funds tracked by Wall St. Rank held Pfizer as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.